OrthogenRx, Inc., a medical device company focused on the development and commercialization of treatments focused on the development and commercialization of treatments for knee pain caused by osteoarthritis (OA), today announced its
| DOYLESTOWN, Pa., Jan. 21, 2021 /PRNewswire/ -- OrthogenRx, Inc.., a medical device company focused on the development and commercialization of treatments focused on the development and commercialization of treatments for knee pain caused by osteoarthritis (OA), today announced its company highlights for 2020 which have exceeded revenue targets. Among many accomplishments, OrthogenRx is proud to have launched new pricing options to facilitate access to affordable healthcare products, needed more than ever during the health and financial crisis of 2020. “OrthogenRx’s mission has been to provide safe and efficacious treatment options to our patients for the treatment of OA knee pain while providing fair and consistent pricing to healthcare professionals and their patients,” said Michael Daley, PhD, Co-President, Co-Chief Executive Officer, and Founder of OrthogenRx, Inc. “All of the employees embody our core values, and have been the hallmark of our ability to not only survive but thrive in the most trying year for healthcare products sales. With additional focus on training, a focused commercial strategy, continued innovation, and a rich product portfolio, we are poised for continued success in 2021.” The company reported the following results and highlights:
“Early in 2020 we focused on leadership and our commercial strategy to optimize customer acceptance, service and experience, and coupled this with what we believe is most ethical business practice. That includes taking care of employees and the local community. Great companies are only possible through great teams!”, said Michael Daley, Co-CEO of OrthogenRx. “I continue to be amazed at the company’s resilience and team performance that created significant value for all the key stakeholders and customers in the most trying of years. Our team continues to be an industry leader in efficiency as assessed by revenue generated per full-time employee equivalent.” 2021 Outlook The company projects it will continue a growth trajectory in 2021 and has experienced significant year over year sales growth since inception. The company is actively recruiting for highly motivated and dedicated team members across the organization, including customer service, marketing, finance, compliance, and quality. Among the operational plans for 2021, the company is planning new innovative products, building strategic partnerships, and delivering superior customer experiences. “Entering 2021, our performance sets the stage for continued growth and product expansion,” added Daley. “As you would expect, we closely monitor all conditions that may impact the business but remain optimistic that we can continue to expand our business at pace and deliver an industry-leading value proposition.” ABOUT OrthogenRx OrthogenRx Inc. is a late-stage development company headquartered in Doylestown, it licenses, develops, and sells equivalent orthopedic medical devices at competitive pricing and efficient operating processes, thereby maintaining favorable margins. This reduced cost to the healthcare system maintains affordable access to quality healthcare. The management team has decades of industry experience in product development, commercialization, sales/marketing, and reimbursement of medical device products. Contacts OrthogenRx Inc. ORTGEN-OGXPR-0121
SOURCE OrthogenRx, Inc. |
View original content:
